What Is Hyrimoz? Uses, Dosage, and What You Need to Know in 2026

Hyrimoz (adalimumab-adaz) is a biologic medication used to treat nine serious inflammatory and autoimmune conditions. Approved by the FDA in 2018, it is a biosimilar to Humira (adalimumab) — meaning it is highly similar to Humira in safety, purity, and effectiveness, and produces no clinically meaningful difference in outcomes. Manufactured by Sandoz Inc., Hyrimoz launched in the U.S. on July 1, 2023, and has quickly become one of the most widely used adalimumab products in the country.

What Conditions Does Hyrimoz Treat?

Hyrimoz is FDA-approved for nine indications:

Rheumatoid Arthritis (RA): Reduces signs and symptoms, inhibits joint damage progression, and improves physical function in adults with moderate-to-severe active RA. Can be used alone or with methotrexate/other non-biologic DMARDs.

Juvenile Idiopathic Arthritis (JIA): Reduces signs and symptoms of moderately-to-severely active polyarticular JIA in patients 2 years and older.

Psoriatic Arthritis (PsA): Reduces signs and symptoms, inhibits structural damage, and improves function in adults with active PsA.

Ankylosing Spondylitis (AS): Reduces signs and symptoms in adults with active AS.

Crohn's Disease (CD): Treats moderately-to-severely active CD in adults and pediatric patients 6 years and older.

Ulcerative Colitis (UC): Treats moderately-to-severely active UC in adults. Note: effectiveness has not been established in patients who lost response to or were intolerant of TNF blockers.

Plaque Psoriasis (Ps): Treats moderate-to-severe chronic plaque psoriasis in adults who are candidates for systemic therapy or phototherapy when other systemic therapies are less appropriate.

Hidradenitis Suppurativa (HS): Treats moderate-to-severe HS in adults. (High-concentration citrate-free formulation only.)

Uveitis: Treats non-infectious intermediate, posterior, and panuveitis in adults and children 2 years and older.

Hyrimoz vs. Humira: What's the Difference?

Both Hyrimoz and Humira contain adalimumab — a fully human monoclonal antibody that targets TNF-alpha. The difference is that Hyrimoz is a biosimilar (produced by a different manufacturer using a similar but not identical biological process), while Humira is the original "reference product" made by AbbVie.

The FDA requires biosimilars to demonstrate they are highly similar to the reference product with no clinically meaningful differences in safety, purity, or potency. Hyrimoz received FDA interchangeable designation — meaning pharmacists can substitute it for Humira (or vice versa) in most states without a new prescription. Hyrimoz has had nearly 120 million patient-days of experience globally before its U.S. launch.

Available Doses and Formulations

Hyrimoz is available in two formulation types:

Low-concentration (50 mg/mL): 10 mg/0.2 mL, 20 mg/0.4 mL, 40 mg/0.8 mL prefilled syringe. Note: Some of these presentations are being discontinued by Sandoz in 2026; equivalent high-concentration formats are available.

High-concentration citrate-free (100 mg/mL): 10 mg/0.1 mL, 20 mg/0.2 mL, 40 mg/0.4 mL, 80 mg/0.8 mL prefilled syringe; 40 mg/0.4 mL and 80 mg/0.8 mL Sensoready Pen (autoinjector). The citrate-free formulation delivers the same dose in a smaller volume and tends to cause less injection site pain.

Standard Dosing by Condition

RA, PsA, AS: 40 mg subcutaneously every other week (some RA patients on methotrexate may benefit from weekly 40 mg)

Plaque Psoriasis: 80 mg initial dose, then 40 mg every other week starting 1 week after initial dose

Crohn's Disease and UC (induction): 160 mg on Day 1, 80 mg on Day 15, then 40 mg every other week starting Day 29

Hidradenitis Suppurativa: 160 mg Day 1, 80 mg Day 15, then 40 mg weekly

Uveitis: 80 mg Day 1, then 40 mg every other week starting 1 week after initial dose

How Is Hyrimoz Given?

Hyrimoz is given as a subcutaneous injection — injected under the skin of the abdomen or front of the thigh. Patients (or caregivers) can administer the injection at home using the Sensoready Pen autoinjector or a prefilled syringe. Your first injection may be given by a nurse, who can also train you on proper technique.

Hyrimoz must be stored in the refrigerator at 36–46°F (2–8°C) and should never be frozen. If traveling, it can be stored at room temperature (up to 77°F/25°C) for up to 14 days, protected from light.

Before Starting Hyrimoz: Required Testing

Tuberculosis (TB) test: Required before starting. Latent TB must be treated first.

Hepatitis B screening: Required to check for chronic HBV carrier status.

Vaccination update: Bring your vaccinations up to date before starting Hyrimoz. Live vaccines cannot be given while on Hyrimoz.

To understand how Hyrimoz works at the biological level, see: How Does Hyrimoz Work? Mechanism of Action Explained in Plain English.

Once your prescription is written, medfinder can help you find Hyrimoz in stock at a pharmacy near you.